Business
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s first quarter 2026 financial results and provide a business update at 8:30 a.m. ET on Tuesday, May 5, 2026. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call u
About this update from Ocugen, Inc.
[{"type":"image","alt":"Ocugen","displaySize":"","headline":null,"caption":"Ocugen","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":171,"url":"https://media.zenfs.com/en/globenewswire.com/11651bb9383edc87dda9630a4828404a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Skm9e_O_sayLZV9VbrxBBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzOQ--/https://media.zenfs.com/en/globenewswire.com/11651bb9383edc87dda9630a4828404a","width":300,"height":171}},"lazy":false},{"type":"text","content":"MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s first quarter 2026 financial results and provide a business update at 8:30 a.m. ET on Tuesday, May 5, 2026.","length":379,"tagName":"p"},{"type":"text","content":"Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:","length":147,"tagName":"p"},{"type":"text","content":"Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 4973685Webcast: Available on the events section of the Ocugen investor site","length":200,"tagName":"p"},{"type":"text","content":"A replay of the call and archived webcast will be available on the Ocugen investor site.","length":93,"tagName":"p"},{"type":"text","content":"About Ocugen, Inc.Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late-stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.Caution...